ALLO-715 is an allogeneic (donor-derived) CAR T cell therapy targeting B-cell maturation antigen (BCMA) that is being developed as a potential novel treatment for multiple myeloma and other BCMA-positive malignancies.
| SparkCures ID | 339 |
|---|---|
| Developed By | Allogene Therapeutics |
| Generic Name | ALLO-715 |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.